Latest total revenue for CLVS: $130M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2022
Trailing 12 months ending Sep 2022
As of the most recent data (September 2022), CLVS shows a total revenue of $130M. That compares with $160M in the prior-year period — down 14.8% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CLVS's total revenue is now $130M (was $160M) — a 14.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Clovis Oncology is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Clovis Oncology is at $130M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how CLVS stacks up against individual peers as well.
Tracking CLVS's total revenue over time shows whether Clovis Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $160M in the prior-year period — down 14.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Clovis Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $130M) with ownership activity and broader fundamentals.